CClinicalTrials.gg
CompletedNCT05572931Updated Feb 20, 2024

Effect of Fu's Subcutaneous Needling on Postoperative Acute Pain in Patients With Lumbar Spine Surgery.

An interventional study of Fu's Subcutaneous Needling(FSN) and fine acupuncture needle in Pain, Postoperative, sponsored by China Medical University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Mar 2021, registered Oct 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate Fu's Subcutaneous Needling (FSN) in postoperative pain in patients with Lumbar Spine Surgery (LSS). The main questions it aims to answer are:

  • Is FSN effective for postoperative pain?
  • Dose FSN decrease the tissue hardness after LSS?
  • Dose FSN have the effect of anti-inflammatory after LSS?

Participants will receive routine analgesic and FSN after LSS. Researchers will compare Sham group to see if FSN being effective for postoperative pain.

02

Conditions studied

  • Pain, Postoperative

Keywords

  • Fu's Subcutaneous Needling, postoperative pain
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 49 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Pain and neurological symptoms are caused by degeneration of the spine (L1-S1) and require surgery.
  • One hour after lumbar spine surgery (evaluated after returning to the ward from the recovery room) Visual analogue scale (VAS) score ≥ 5 points
  • After being explained, join the trial voluntarily and sign the subject's consent form.

Exclusion criteria

Exclusion Criteria:

  • Pain caused by acute trauma.
  • major diseases such as heart and lung failure, cancer, chronic kidney disease.
  • psychiatric disorder.
  • History of substance abuse.
  • A history of spinal surgery.
  • Refused sign the consent form.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Sham comparator
    Sham comparator

    In addition to the routine analgesic (Acetaminophen 500mg, TID), the patients were treated with sham FSN at the 1st, 24th, and 48th hours after surgery. The sham FSN was used a fine acupuncture needle without swaying movement and reperfusion approach.

    Device: fine acupuncture needle

  • Experimental
    Experimental

    In addition to postoperative routine analgesic (Acetaminophen 500mg, TID), patients were received FSN treatment. The FSN insertion point and time are the same as control group. And then we performed swaying movement and reperfusion approach.

    Device: Fu's Subcutaneous Needling(FSN)

Interventions

  • DeviceFu's Subcutaneous Needling(FSN)

    Insertion points are both sides of 1) inferior edge of the scapula; 2)the midpoint of inferior edge of the posterior superior iliac spine and the ischial tuberosity. FSN (Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.) ) is a solid needle with plastic cannula tube on the outside. Add on swaying movement (SM) and reperfusion approach (RA) after the needle inserting into the subcutaneous layer. The SM is a horizontal fan sway movement with the base of the needle for the fulcrum, The SM speed is 200 times in 2 minutes. Apply RA when performing SM. RA movement is hip extension in prone position with resistance by physician's hand for 10 seconds. And then rest for 10 seconds. Repeat 3 cycles. The same RA is performed over the other three insertion point.

  • Devicefine acupuncture needle

    (36G, 0.5 inch, Wujiang city cloud \& dragon medical device Co.,Ltd.) Only inserted to skin, not into the subcutaneous layer. No SM and RA.

06

What researchers measure

Primary outcomes

  1. Change of Taiwanese version of the Brief Pain Inventory (BPI-T) Short Form

    BPI-T Short Form

    Time frame: Change from Baseline BPI-T at the 1st、24th、48th、72nd hour after surgery.

  2. The total dosage of analgesic drug

    opioid drug (Pethidine 50mg/vail)

    Time frame: The amount of intravenous opioid drug (Pethidine 50mg/vail) within 72 hours after surgery.

Secondary outcomes

  1. Change of Blood serum C-reactive protein (CRP)

    Biochemistry

    Time frame: Change from Baseline CRP at the 24th, 72nd hour, 1st month after surgery.

  2. Change of Blood serum IL-1ẞ、IL-2、IL-6

    Biochemistry

    Time frame: Change from Baseline IL-1ẞ、IL-2、IL-6 at the 24th, 72nd hour, 1st month after surgery.

  3. Change of Blood serum TNF-α

    Biochemistry

    Time frame: Change from Baseline TNF-α at the 24th, 72nd hour, 1st month after surgery.

  4. Change of Tissue hardness (TH)

    The points for measuring TH were the inferior border of the scapula, two centimeters horizontal from the midline of the L3 level, and the gluteus maximus.

    Time frame: Change from Baseline TH at the 1st、24th、48th、72nd hour after surgery.

07

Study locations

1 site
  • China Medical University Hsinchu Hospital
    Zhubei, Hsinchu County 302, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05572931
Lead sponsor
China Medical University Hospital
Responsible party
Chih-Ying Wu (Attending physician, China Medical University Hospital) — Principal investigator
First posted
Oct 10, 2022
Start date
Mar 8, 2021
Primary completion
Feb 1, 2023
Completion
Jun 25, 2023
Last update
Feb 20, 2024

Study contacts

Chih-Ying Wu, MD
study chair · China Medical University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion